1Kohli P & Greenland P (2006) Role of the metabolic syndrome in risk assessment for coronary heart disease. JAMA 295, 819–821.
2Cortez-Dias N, Martins S & Fiuza M (2007) Metabolic syndrome: an evolving concept. Rev Port Cardiol 26, 1409–1421.
3Anderson RA, Cheng N, Bryden NA, et al. (1997) Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 46, 1786–1791.
4Fernandez-Mejia C (2005) Pharmacological effects of biotin. J Nutr Biochem 16, 424–427.
5Wang ZQ, Zhang XH, Baldor LC, et al. (2000) Chromium picolinate enhances insulin sensitivity in an animal model for the metabolic syndrome: the obese, insulin resistant JCR:LA-corpulent rat (abstract). Diabetes 49, A71.
6Komorowski JR, Greenberg D, Maki KC, et al. (2001) Chromium picolinate with biotin attenuates elevation in blood glucose levels in people with type two diabetes ingesting medium carbohydrate nutritional beverages (abstract). J Am Coll Nutr 20, A73.
7Albarracin CA, Fuqua BC, Evans JL, et al. (2008) Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 24, 41–51.
8Singer GM & Geohas J (2006) The effect of chromium picolinate and biotin supplementation on glycemic control in poorly controlled patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial. Diabetes Technol Ther 8, 636–643.
9Juturu V, Ruelle A, Hudson MS, et al. (2006) Improved glycemic control after diabetes education and chromium picolinate/biotin supplementation in type 2 diabetes: results from patients experience pilot program. Trace Elem Electrolytes 23, 66–72.
10Geohas J, Daly A, Juturu V, et al. (2007) Chromium picolinate and biotin combination reduces atherogenic index of plasma in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial. Am J Med Sci 333, 145–153.
11Hallakou S, Doaré L, Foufelle F, et al. (1997) Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes 46, 1393–1399.
12Saad MJ, Araki E, Miralpeix M, et al. (1992) Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance. J Clin Invest 90, 1839–1849.
13Gilmore JL, King BW, Harris C, et al. (2006) Synthesis and structure–activity relationship of a novel, achiral series of TNF-alpha converting enzyme inhibitors. Bioorg Med Chem Lett 16, 2699–2704.
14Hua Y, Clark S, Ren J, et al. (2012) Molecular mechanisms of chromium in alleviating insulin resistance. J Nutr Biochem 23, 313–319.
15Sharma AK, Bharti S, Ojha S, et al. (2011) Up-regulation of PPARγ, heat shock protein-27 and -72 by naringin attenuates insulin resistance, β-cell dysfunction, hepatic steatosis and kidney damage in a rat model of type 2 diabetes. Br J Nutr 106, 1713–1723.
16Reeves PG, Nielsen FH & Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123, 1939–1951.
17Matsuda M & De Fronzo RA (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 22, 1462–1470.
18Muniyappa R, Chen H, Muzumdar RH, et al. (2009) Comparison between surrogate indexes of insulin sensitivity/resistance and hyperinsulinemic euglycemic clamp estimates in rats. Am J Physiol Endocrinol Metab 297, 1023–1029.
19Karatepe M (2004) Simultaneous determination of ascorbic acid and free malondialdehyde in human serum by HPLC/UV. LC GC N Am 22, 362–365.
20Ross MH, Reith EJ & Romrell LJ (1989) Histology. A Text and Atlas (Kimberly Kist), 2nd ed.Baltimore, MD: Williams and Wilkins.
21Arvind K, Pradeepa R, Deepa R, et al. (2002) Diabetes and coronary artery disease. Indian J Med Res 116, 163–176.
22Zheng XK, Zhang L, Wang WW, et al. (2011) Anti-diabetic activity and potential mechanism of total flavonoids of Selaginella tamariscina (Beauv.) spring in rats induced by high fat diet and low dose STZ. J Ethnopharmacol 137, 662–668.
23Sahin K, Tuzcu M, Orhan C, et al. (2011) The effects of chromium complex and level on glucose metabolism and memory acquisition in rats fed high-fat diet. Biol Trace Elem Res 143, 1018–1030.
24Preuss HG, Echard B, Perricone NV, et al. (2008) Comparing metabolic effects of six different commercial trivalent chromium compounds. J Inorg Biochem 102, 1986–1990.
25Jain SK, Croad JL, Velusamy T, et al. (2010) Chromium dinicocysteinate supplementation can lower blood glucose, CRP, MCP-1, ICAM-1, creatinine, apparently mediated by elevated blood vitamin C and adiponectin and inhibition of NFkappaB, Akt, and Glut-2 in livers of zucker diabetic fatty rats. Mol Nutr Food Res 54, 1371–1380.
26Akude E, Zherebitskaya E, Chowdhury SK, et al. (2011) Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats. Diabetes 60, 288–297.
27Derosa G & Maffioli P (2012) Peroxisome proliferator-activated receptor-γ (Ppar-γ) agonists on glycemic control, lipid profile and cardiovascular risk. Curr Mol Pharmacol 5, 272–281.
28Benigni A, Zoja C, Campana M, et al. (2006) Beneficial effect of TGFbeta antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol 104, 158–168.
29Panchapakesan U, Chen XM & Pollock CA (2005) Drug insight: thiazolidinediones and diabetic nephropathy-relevance to renoprotection. Nat Clin Pract Nephrol 1, 33–43.
30Bobulescu IA (2010) Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 19, 393–402.
31Shen W, Hao J, Tian C, et al. (2008) A combination of nutriments improves mitochondrial biogenesis and function in skeletal muscle of type 2 diabetic Goto–Kakizaki rats. PLoS One 3, e2328.
32Khan HB, Vinayagam KS, Moorthy BT, et al. (2012) Anti-inflammatory and anti-hyperlipidemic effect of Semecarpus anacardium in a high fat diet: STZ-induced type 2 diabetic rat model. Inflammopharmacology .
33Reddi A, DeAngelis B, Frank O, et al. (1988) Biotin supplementation improves glucose and insulin tolerances in genetically diabetic KK mice. Life Sci 42, 1323–1330.
34Zhang H, Osada K, Sone H, et al. (1997) Biotin administration improves the impaired glucose tolerance of streptozocin-induced diabetic Wistar rats. J Nutr Sci Vitaminol (Tokyo) 43, 271–280.
35Cheatham B & Kahn CR (1995) Insulin action and the insulin signaling network. Endocr Rev 16, 117–142.
36Wang ZQ, Zhang XH, Russell JC, et al. (2006) Chromium picolinate enhances skeletal muscle cellular insulin signaling in vivo in obese, insulin-resistant JCR:LA-cp rats. J Nutr 136, 415–420.
37Kuhad A & Chopra K (2009) Tocotrienol attenuates oxidative-nitrosative stress and inflammatory cascade in experimental model of diabetic neuropathy. Neuropharmacology 57, 456–462.
38Kuhad A, Sachdeva AK & Chopra K (2009) Attenuation of renoinflammatory cascade in experimental model of diabetic nephropathy by sesamol. J Agric Food Chem 57, 6123–6128.
39Cheng CF, Chen HH & Lin H (2010) Role of PPARα and its agonist in renal diseases. PPAR Res .
40Tuzcu M, Sahin N, Orhan C, et al. (2011) Impact of chromium histidinate on high fat diet induced obesity in rats. Nutr Metab (Lond) 3, 8:28.
41Zhang H, Osada K, Maebashi M, et al. (1996) A high biotin diet improves the impaired glucose tolerance of long-term spontaneously hyperglycemic rats with non-insulin-dependent diabetes mellitus. J Nutr Sci Vitaminol (Tokyo) 42, 517–526.